Fagron NV (FAGR) | Financial Analysis & Statements
Fagron NV Large-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2019Income Metrics
EPS (Diluted)
€0.00
Balance Sheet Metrics
Total Assets
1.2B
Total Liabilities
686.9M
Shareholders Equity
556.3M
Debt to Equity
1.23
Cash Flow Metrics
Revenue & Profitability Trend
Annual Income Flow
2025
Fagron NV Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 952.2M | 872.0M | 763.0M | 683.9M | 573.8M |
| Cost of Goods Sold | 520.2M | 476.3M | 430.4M | 397.7M | 326.3M |
| Gross Profit | 432.0M | 395.7M | 332.6M | 286.2M | 247.5M |
| Gross Margin % | 45.4% | 45.4% | 43.6% | 41.8% | 43.1% |
| Operating Expenses | |||||
| Research & Development | - | - | - | - | - |
| Selling, General & Administrative | - | - | - | - | - |
| Other Operating Expenses | 6.0M | 4.2M | 2.3M | 6.1M | 2.3M |
| Total Operating Expenses | 6.0M | 4.2M | 2.3M | 6.1M | 2.3M |
| Operating Income | 147.5M | 134.4M | 112.7M | 101.2M | 89.9M |
| Operating Margin % | 15.5% | 15.4% | 14.8% | 14.8% | 15.7% |
| Non-Operating Items | |||||
| Interest Income | 4.1M | 4.4M | 5.3M | 4.1M | 1.4M |
| Interest Expense | 19.8M | 17.4M | 15.2M | 10.6M | 8.0M |
| Other Non-Operating Income | - | - | - | - | - |
| Pre-tax Income | 117.6M | 104.3M | 84.4M | 87.8M | 76.8M |
| Income Tax | 26.1M | 23.3M | 13.4M | 17.7M | 15.4M |
| Effective Tax Rate % | 22.2% | 22.3% | 15.9% | 20.2% | 20.1% |
| Net Income | 91.5M | 81.0M | 71.0M | 70.1M | 61.4M |
| Net Margin % | 9.6% | 9.3% | 9.3% | 10.2% | 10.7% |
| Key Metrics | |||||
| EBITDA | 182.6M | 164.0M | 141.9M | 128.2M | 112.4M |
| EPS (Basic) | €1.25 | €1.10 | €0.97 | €0.96 | €0.84 |
| EPS (Diluted) | €1.24 | €1.10 | €0.97 | €0.96 | €0.84 |
| Basic Shares Outstanding | 73077626 | 72937168 | 73000000 | 72875000 | 72643000 |
| Diluted Shares Outstanding | 73077626 | 72937168 | 73000000 | 72875000 | 72643000 |
Income Statement Trend
Fagron NV Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 184.9M | 115.0M | 133.0M | 125.3M | 70.6M |
| Short-term Investments | 11.0K | 886.0K | 4.3M | 451.0K | - |
| Accounts Receivable | 95.2M | 82.0M | 62.1M | 60.7M | 51.9M |
| Inventory | 158.9M | 137.0M | 113.9M | 108.3M | 90.8M |
| Other Current Assets | 23.8M | 27.7M | 22.6M | 23.2M | -2.0K |
| Total Current Assets | 462.8M | 362.6M | 335.9M | 318.0M | 233.7M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 219.6M | 193.1M | 172.7M | 165.6M | 136.6M |
| Goodwill | 1.0B | 955.3M | 917.3M | 893.2M | 791.5M |
| Intangible Assets | 99.7M | 61.4M | 48.6M | 33.6M | 30.7M |
| Long-term Investments | 317.0K | 553.0K | 2.5M | 13.3M | 1.2M |
| Other Non-Current Assets | - | - | - | - | - |
| Total Non-Current Assets | 780.3M | 721.0M | 671.1M | 653.0M | 566.7M |
| Total Assets | 1.2B | 1.1B | 1.0B | 971.0M | 800.4M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 137.6M | 114.3M | 104.9M | 97.9M | 83.7M |
| Short-term Debt | 11.6M | 9.5M | 9.7M | 19.0M | 14.3M |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 1.0K | -1.0K | - | 2.0K | 1.0K |
| Total Current Liabilities | 219.0M | 194.7M | 175.3M | 171.0M | 145.1M |
| Non-Current Liabilities | |||||
| Long-term Debt | 456.6M | 376.2M | 357.1M | 380.4M | 321.3M |
| Deferred Tax Liabilities | 5.4M | 1.8M | 2.0M | 4.4M | 2.5M |
| Other Non-Current Liabilities | - | - | - | -1.0K | 1.0K |
| Total Non-Current Liabilities | 467.9M | 383.4M | 364.1M | 389.5M | 329.9M |
| Total Liabilities | 686.9M | 578.2M | 539.3M | 560.5M | 475.0M |
| Equity | |||||
| Common Stock | 532.9M | 524.5M | 524.5M | 521.2M | 520.8M |
| Retained Earnings | 330.8M | 264.9M | 206.3M | 150.3M | 95.3M |
| Treasury Stock | 28.1M | 23.9M | 21.1M | 18.8M | 18.8M |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | 556.3M | 505.4M | 467.6M | 410.5M | 325.5M |
| Key Metrics | |||||
| Total Debt | 468.2M | 385.7M | 366.7M | 399.4M | 335.6M |
| Working Capital | 243.9M | 167.9M | 160.6M | 147.0M | 88.6M |
Balance Sheet Composition
Fagron NV Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | 117.6M | 104.3M | 84.4M | 87.8M | 76.8M |
| Depreciation & Amortization | - | - | - | - | - |
| Stock-Based Compensation | 1.0M | 1.2M | 2.4M | 1.8M | 3.3M |
| Working Capital Changes | -11.5M | -34.8M | -6.3M | -2.1M | -22.7M |
| Operating Cash Flow | 135.7M | 97.1M | 104.8M | 92.1M | 68.0M |
| Investing Activities | |||||
| Capital Expenditures | -15.4M | -14.6M | -20.3M | - | - |
| Acquisitions | -69.7M | -28.9M | -6.3M | -50.8M | -11.2M |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -85.1M | -43.5M | -26.6M | -50.8M | -11.2M |
| Financing Activities | |||||
| Share Repurchases | -4.1M | -2.9M | -2.3M | 0 | - |
| Dividends Paid | -26.0M | -21.0M | -18.3M | -14.6M | -13.0M |
| Debt Issuance | 171.3M | 52.5M | 0 | 135.0M | 66.2M |
| Debt Repayment | -89.4M | -44.0M | -28.0M | -85.7M | -99.5M |
| Financing Cash Flow | 64.8M | -11.1M | -39.9M | 38.7M | -38.0M |
| Free Cash Flow | 124.6M | 69.1M | 86.2M | 91.0M | 57.7M |
| Net Change in Cash | 115.4M | 42.5M | 38.2M | 80.1M | 18.9M |
Cash Flow Trend
Fagron NV Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
19.15
Forward P/E
14.43
Price to Book
3.15
Price to Sales
1.83
Profitability Ratios
Profit Margin
9.56%
Operating Margin
15.08%
Return on Equity
17.24%
Return on Assets
7.79%
Financial Health
Current Ratio
2.11
Debt to Equity
84.34
Beta
0.33
Per Share Data
EPS (TTM)
€1.24
Book Value per Share
€7.53
Revenue per Share
€13.03
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| FAGR | 1.7B | 19.15 | 3.15 | 17.24% | 9.56% | 84.34 |
| Argenx SE | 41.4B | 39.84 | 6.59 | 20.15% | 30.50% | 0.64 |
| Ion Beam | 411.9M | 33.21 | 3.78 | 0.00% | 2.05% | 0.56 |
| Onward Medical N.V | 204.4M | - | 2.98 | -80.85% | 72.51% | 24.70 |
Financial data is updated regularly. All figures are in the company's reporting currency.